文献速递组学、生物样本库与精准医学基础与转化研究医学人工智能与信息学

全球神经退行性疾病蛋白质组学联盟:常见神经退行性疾病与衰老的生物标志物及药物靶点发现

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.
PubMed 文献 · Nat Med · 2025-07-15

该数据集于2025年7月15日向更广泛的研究社区开放,血浆蛋白质组分析揭示了疾病特异性差异蛋白丰度、跨诊断的临床严重程度特征以及APOE ε4携带状态的稳健特征。

要点

  • 血浆蛋白质组分析揭示疾病特异性差异蛋白丰度和跨诊断的临床严重程度特征。
  • 发现跨AD、PD、FTD和ALS可重复的APOE ε4携带状态血浆蛋白质组特征及器官衰老模式。

核心结论

  • GNPC通过国际合作、数据共享和开放科学建立了大规模协调蛋白质组数据集,展示其加速神经退行性疾病研究发现的潜力。

主要发现

  • 血浆蛋白质组总结分析揭示了疾病特异性差异蛋白丰度和跨诊断的临床严重程度蛋白质组特征。
  • 描述了APOE ε4携带状态的稳健血浆蛋白质组特征,该特征在阿尔茨海默病、帕金森病、额颞叶痴呆和肌萎缩侧索硬化中可重复。
  • 描述了这些疾病中不同的器官衰老模式。

临床怎么用

  • 数据集可通过阿尔茨海默病数据倡议的AD Workbench安全云环境供GNPC成员访问,并将于2025年7月15日向更广泛的研究社区开放。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging and subtyping of these conditions. High-dimensional molecular studies in biofluids ('omics') offer promise for scalable biomarker discovery, but challenges in assembling large, diverse datasets hinder progress. To address this, the Global Neurodegeneration Proteomics Consortium (GNPC)-a public-private partnership-established one of the world's largest harmonized proteomic datasets. It includes approximately 250 million unique protein measurements from multiple platforms from more than 35,000 biofluid samples (plasma, serum and cerebrospinal fluid) contributed by 23 partners, alongside associated clinical data spanning Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). This dataset is accessible to GNPC members via the Alzheimer's Disease Data Initiative's AD Workbench, a secure cloud-based environment, and will be available to the wider research community on 15 July 2025. Here we present summary analyses of the plasma proteome revealing disease-specific differential protein abundance and transdiagnostic proteomic signatures of clinical severity. Furthermore, we describe a robust plasma proteomic signature of APOE ε4 carriership, reproducible across AD, PD, FTD and ALS, as well as distinct patterns of organ aging across these conditions. This work demonstrates the power of international collaboration, data sharing and open science to accelerate discovery in neurodegeneration research.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Imam F, Saloner R, Vogel JW, et al. The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. Nat Med. 2025. PMID: 40665048. doi:10.1038/s41591-025-03834-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。